A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.
Epistemonikos ID: fe368e7472b80d418f0c175783ec2738b03014de
First added on: Oct 01, 2024